肌苷二醛 | 23590-99-0

• 物质功能分类: 原料药 - 抗肿瘤药 - 抗代谢类抗肿瘤药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 肌苷二醛
• 中文别名: 次黄嘌呤核苷醛
• 英文名称: inosinedialdehyde
• 英文别名: D-Glycerinaldehyd-2-；Inosin-dialdehyd；2-O-((R)-Formyl-(hypoxanthinyl-(9))-methyl)-(R)-glycerinaldehyd；2-O-((R)-Formyl-(hypoxanthinyl-(9))-methyl)-(R)-glycerinaldehyd, Inosin-2,3-dialdehyd；[R-(R*, R*)]-α-(1-Formyl-2-hydroxyethoxy)-1,6-dihydro-6-oxo-9H-purine-9-acetaldehyde；3-hydroxy-2-[2-oxo-1-(6-oxo-1,6-dihydro-purin-9-yl)-ethoxy]-propionaldehyde；Inosine dialdehyde；(2R)-3-hydroxy-2-[(1R)-2-oxo-1-(6-oxo-1H-purin-9-yl)ethoxy]propanal
• CAS: 23590-99-0
• 化学式: C₁₀H₁₀N₄O₅
• 分子量: 266.213
• InChiKey: RGWOFTGZWJGPHG-NKWVEPMBSA-N

物化性质

• 熔点：
  148-150 °C(Solv: ethanol (64-17-5))
• 沸点：
  626.1±55.0 °C(Predicted)
• 密度：
  1.69±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  肌苷二醛 在 次磷酸 作用下， 以 甲醇 、 水 为溶剂， 生成 (2S,3S)-2-[3-Hydroxy-6-hydroxymethyl-5-hydroxyphosphinoyl-2-(6-oxo-1,6-dihydro-purin-9-yl)-morpholin-4-yl]-3-methyl-pentanoic acid
  参考文献：
  名称：

  Synthesis and antiviral activity of hydrophosphorylated inosines

  摘要：

  DOI：

  10.1007/bf00767031

文献信息

• 3,5-Di hydroxy morpholine derivatives and pharmaceutical compositions
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04558047A1

  公开（公告）日：1985-12-10

  3,5-Di hydroxy morpholine derivatives having antitumor activity and methods of preparation thereof, are disclosed.

  3,5-二羟基吗啉衍生物具有抗肿瘤活性及其制备方法。
• Morpholine derivatives, processes for the preparation thereof, the use thereof and pharmaceutical compositions containing them
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0123473A2

  公开（公告）日：1984-10-31

  The present invention provides compounds of the formula: wherein R' is a uracilyl, cytosinyl, hypoxanthinyl, adeninyl or thiazolyl radical, which may be substituted by halogen or carbamoyl; R2 is a nitrogen-containing unsaturated heterocyclic radical, which may be substituted by oxo or lower alkyl; and R3 is a hydrogen atom or a phosphono group; and the pharmaceutically-acceptable salts thereof. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them and provides a method of treating cancer which comprises administering these compounds to humans and animals.

  本发明提供了式中化合物： 其中 R'是尿嘧啶基、胞嘧啶基、次黄嘌呤基、腺嘌呤基或噻唑基，可被卤素或氨基甲酰基取代； R2 是含氮不饱和杂环基，可被氧代或低级烷基取代；以及 R3 是氢原子或膦酰基；及其药学上可接受的盐类。 本发明还提供了制备这些化合物和含有这些化合物的药物组合物的工艺，并提供了一种治疗癌症的方法，该方法包括向人和动物施用这些化合物。
• Bi-functional complexes and methods for making and using such complexes
  申请人：Gouliaev Alex Haahr

  公开号：US11225655B2

  公开（公告）日：2022-01-18

  The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.

  本发明涉及一种合成双功能复合物的方法，该复合物包括分子部分和识别分子部分的识别寡核苷酸部分。根据本发明的合成方法的一部分优选在一种或多种有机溶剂中进行，此时包含可选保护标签或寡核苷酸标识符的新生双功能复合物与固体支持物相连接，合成方法的另一部分优选在适合于将寡核苷酸标签酶加到溶液中的新生双功能复合物的条件下进行。
• BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES
  申请人：Nuevolution A/S

  公开号：EP2558577A1

  公开（公告）日：2013-02-20
• BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES
  申请人：Gouliaev Alex Haahr

  公开号：US20130281324A1

  公开（公告）日：2013-10-24

  The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.